Annual Drug Patent Expirations for ADEMPAS
Adempas is a drug marketed by Bayer Hlthcare and is included in one NDA. It is available from one supplier. There are two patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for ADEMPAS.
This drug has sixty-seven patent family members in forty-three countries.
The generic ingredient in ADEMPAS is riociguat. One supplier is listed for this compound. Additional details are available on the riociguat profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com